Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Inventiva S.A.NASDAQ: IVA
Gross Profit · Q4 FY2025 · quarter ended Dec 2025
Gross profit turns negative
Q4 FY2025 gross profit was -€1.17M, compared with €6.99M a year earlier. Over 3 fiscal years it compounded at -55.4% a year.
Context
- Gross profit amounted to 33.7% of revenue in FY2025, down 66.3 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
EUR · from the income statement
- Latest · FY2025
- 1.51M EUR
- Year-over-year change
- -83.6%
- 4-year CAGR
- -22.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.51M | -83.6% |
| FY2024 | 2024-12-31 | 9.2M | -47.4% |
| FY2023 | 2023-12-31 | 17.5M | +2.6% |
| FY2022 | 2022-12-31 | 17.06M | +306.7% |
| FY2021 | 2021-12-31 | 4.19M | — |
Gross Profit vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -83.6% is the 8th highest of 10, against a peer median of +43.5%.
- Gross profit amounts to 33.7% of revenue for IVA, versus a peer median of 99.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $68M USD | +5.5% | -11.0% | 98.3% | |
| LTM Mar 2026 | $51.41M USD | +50.2% | — | 92.0% | |
| LTM Mar 2026 | $32.49M USD | +1115.8% | +118.1% | 99.3% | |
| LTM Mar 2026 | $9.26M USD | +117.7% | -9.7% | 82.6% | |
| FY2025 | €1.51M EUR | -83.6% | -55.4% | 33.7% | |
| LTM Mar 2026 | $326K USD | +115.4% | — | 144.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$151.18K USD | -13.6% | — | — |
| LTM Mar 2026 | -$6.32M USD | +43.5% | — | — | |
| LTM Mar 2026 | -$10.62M USD | -104.7% | -84.1% | 17996.6% | |
| LTM Mar 2026 | -$11.02M USD | -132.3% | -70.5% | 621.0% | |
| Peer median (excluding IVA) | — | +43.5% | -11.0% | 99.3% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.19M | 12.18M | 17.48M | 9.2M | 4.48M |
| Cost of Revenue | 1.02M | 995K | (23K) | 3.88M | 2.8M |
| Gross Profit | 4.19M | 17.06M | 17.5M | 9.2M | 1.51M |
| Gross Margin | 100.0% | 140.1% | 100.1% | 100.0% | 33.7% |
| Research & Development | 48.45M | 60.47M | 110.01M | 90.88M | 83.61M |
| Selling, General & Admin | 11.52M | 15.5M | 15.61M | 17.1M | 53.89M |
| Operating Expenses | 56.31M | 74.17M | 120.19M | 106.76M | 137.37M |
| Depreciation & Amortization | 858K | 870K | 2.6M | 5.2M | 2.8M |
| EBITDA | (52.76M) | (56.29M) | (102.04M) | (166.53M) | (128.15M) |
| EBITDA Margin | -1258.0% | -462.2% | -583.9% | -1810.4% | -2858.6% |
| Operating Income | (52.11M) | (57.11M) | (102.71M) | (97.56M) | (130.95M) |
| Operating Margin | -1242.6% | -468.9% | -587.7% | -1060.6% | -2921.0% |
| Interest Income | 57K | 390K | 945K | 1.14M | 2.83M |
| Interest Expense | 138K | 707K | 5.18M | 12.18M | 32.3M |
| Other Income / Expenses | 2.84M | 2.82M | (7.11M) | (86.34M) | (211.38M) |
| Income Before Tax | (49.27M) | (54.29M) | (109.82M) | (183.9M) | (342.33M) |
| Pre-Tax Margin | -1174.8% | -445.8% | -628.4% | -1999.4% | -7636.1% |
| Income Tax Expense | 364K | (20K) | 607K | 313K | 22K |
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Net Margin | -1183.5% | -445.6% | -631.8% | -2002.7% | -7587.8% |
| EPS (Basic) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| EPS (Diluted) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| Weighted Avg Shares | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
| Weighted Avg Shares (Diluted) | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.